Table 1.

Patients characteristics from patients included in the PBMC study for TCR V-beta CDR3 sequencing.

Patient Study#	Sex (M/F)	Eth.	Age	Active Metastasis site	LDH	Stage	Mutational status	Toxicities*	Response at EOS	PFS (mo)	OS (mo)
GA 5	M	C	65	Skin, LN, Adrenal	N	M1c	BRAF V600E	-	PR (but PD after EOS)	7	20
GA 7	M	C	62	Skin	N	IIIc	BRAF_V600E	G2 Pruritus	PD	2	67
GA 8	F	C	48	S.C.	High	M1c	BRAF_V600E	G2 Diarrhea	PD	1	3
GA 9	M	C	52	LN, Bone	High	M1c	BRAF_V600E	-	PD	3	14
GA 11	M	C	47	LN	High	M1c	NRAS_Q61R	-	PD	2	7
GA 12	M	C	76	Skin	High	M1c	BRAF_V600E	G3 Colitis	Off due to AE/PD	2	20
GA 13	M	C	37	LN	N	M1a	BRAF_V600E	G2 Hypophysitis	PD	3	13
GA 14	M	C	38	SC, Muslce	High	M1c	HRAS_G12D BRAF_V600E PTEN_N323fs	G1 Diarrhea	PD	3	15
GA 15	M	C	58	Brain, Bowel, Liver	N	M1c	NRAS_Q61R	G3 Rash	PD	4	15
GA 18	F	C	49	Skin	N	M1a	NRAS_Q61R	G1 Diarrhea	CR	62+	62+
GA 19	M	C	55	LN, Brain	N	M1c	NRAS_Q61R TP53_R175H CTNNB1_S37F	G3 Diarrhea G2 Rash	PD	3	36
GA 21	M	C	71	Skin, SC, LN, Liver, Spleen	High	M1c	KIT_L576P	-	PD	3	8
GA 23	M	C	27	Lung	N	M1b		-	PD	2	4
GA 24	M	C	81	SC, Lung	High	M1c	Not detected	G1 Nausea	PD	2	3
GA 25	M	H	71	LN	High	M1c	KIT_N822K	-	PD	3	8
GA 26	M	C	68	LN, Lung	N	M1b	BRAF_V600E	G3 Diarrhea G1 Grover’s	PD	1	51
GA 27	M	C	52	Axillary, Clavicular	High	M1c	BRAF_V600E CDKN2A_E61* PIK3CA_3545K	G2 Pruritus G1 Diarrhea G1 Hypophysitis	PD	6	11
GA 28	M	C	48	LN, Lung	High	M1c	BRAF_G466E EGFR_P753S ABL1_E255K	-	PD	2	4
GA 29	F	C	79	Skin, S.C.	N	IIIc	BRAF_V600E KIT_V559A	G3 Diarrhea G1 Pruritus	CR	45	45
GA 32	M	C	36	Muscle	N	M1c		-	PD	5	56
GA 33	F	C	49	Skin	N	IIIc	BRAF_V600E	G2 Adrenal insuficiency	CR	55+	55+

M: Male; F: Female; C: Caucasian; H: Hispanic; LN: Lymph nodes; SC: Subcutaneous; N: Normal; Neg: Negative. EOS: End of study; PD: Progressive disease; PR: Partial response; CR: Complete response; AE: Adverse effects: PFS: Progression free survival; OS: Overall survival